Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | TLR4 | O00206 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.65 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985918 | 0.91 | DHFR (0.71) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL29658170 | 0.91 | DHFR (0.71) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL221621 | 0.91 | DHFR (0.71) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL18250751 | 0.90 | DHFR (0.59) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| Hydrochloric Acid SCHEMBL1230259 | 0.90 | DHFR (0.70) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| Hydrochloric Acid SCHEMBL3171572 | 0.89 | DHFR (0.69) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL21698576 | 0.89 | DHFR (0.66) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL22201137 | 0.88 | HDAC4 (0.70) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL14400777 | 0.88 | HDAC4 (0.73) | DHFRHDAC4HDAC7HDAC9HDAC5 | |
| SCHEMBL13186954 | 0.87 | DHFR (0.59) | DHFRHDAC4HDAC7HDAC9HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MICROMASS UK LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
| US-8680319-B2 | Method for producing antifolate agents having glutamic acid part in their structure | KOCAK FARMA ILAC VE KIMYA SAN. A.S (TR) | 2014-03-25 | — | — | US | disclosed |
| US-8580921-B2 | Protein nanorings | UNIVERSITY OF MINNESOTA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130253192-A1 | Method for producing antifolate agents having glutamic acid part in their structure | KOCAK FARMA ILAC VE KIMYA SAN. A.S (TR) | 2013-09-26 | — | — | US | disclosed |
| US-20130059359-A1 | Protein Nanorings | UNIVERSITY OF MINNESOTA (US) | 2013-03-07 | — | — | US | disclosed |
| US-8236925-B1 | Protein nanorings | UNIVERSITY OF MINNESOTA (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | FARDIS MARIA | 2009-06-18 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432273-B2 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432273-B2 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | TYMP, PHOSPHO1, PHPT1 | DHFR 373/4885HDAC4 2360/4885HDAC7 2847/4885 |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | DHFR 911/4885HDAC4 977/4885HDAC7 1226/4885 |
| US-20130253192-A1 | Method for producing antifolate agents having glutamic acid part in their structure | GLUL, DHFR, FOLH1 | DHFR 2/4885HDAC4 2893/4885HDAC7 1297/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | DHFR 2043/4885HDAC4 1379/4885HDAC7 2167/4885 |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | TYMP, PHOSPHO1, PHPT1 | DHFR 373/4885HDAC4 2360/4885HDAC7 2847/4885 |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MTX1, MTX2, MTHFD1 | DHFR 8/4885HDAC4 3854/4885HDAC7 4295/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | DHFR 1399/4885HDAC4 586/4885HDAC7 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.